Investigating the genetic and brain structure factors behind neuropsychiatric symptoms in Alzheimer's disease across diverse populations.
Official title: Genetic and neuroanatomical basis of neuropsychiatric symptoms in Alzheimer's disease in populations of diverse ancestry
Funded at Columbia University Health Sciences · NIH-10889915 · Data updated 2026-11-12
This study is looking at how genes and brain structure might affect feelings like aggression and anxiety in people with Alzheimer's, especially focusing on those from different backgrounds, to help find better ways to support and treat them.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | August 1, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $759,900 |
| NIH project number | 5U01AG079850-02 |
| Project ID | NIH-10889915 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with Alzheimer's disease, particularly those exhibiting neuropsychiatric symptoms and belonging to diverse racial and ethnic backgrounds.
✕Less likely to help
Patients without a diagnosis of Alzheimer's disease or those not exhibiting neuropsychiatric symptoms may not benefit from this research.
What this research studies
This research focuses on understanding the genetic and neuroanatomical factors that contribute to neuropsychiatric symptoms, such as aggression and anxiety, in patients with Alzheimer's disease. By studying a diverse group of individuals, including those from underserved racial and ethnic backgrounds, the research aims to fill the knowledge gap regarding these symptoms and their impact on patient care. The approach involves analyzing genetic data and brain imaging from a large cohort of approximately 60,000 individuals to identify patterns and potential treatment targets. This could lead to more effective interventions tailored to the needs of diverse populations.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments for neuropsychiatric symptoms in Alzheimer's patients, enhancing their quality of life.
How similar studies have gone: Previous research initiatives focusing on diverse populations in Alzheimer's disease have shown promise, indicating that this approach could yield valuable insights.
Where this research is happening
-
Columbia University Health Sciences
New York, United States Active
Researchers
- Principal investigator: Reitz, Christiane — Columbia University Health Sciences
- Study coordinator: Reitz, Christiane
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.